TRU-SENTIMENT · DeltaNeutral
IOVA Trading Analysis - 10/30/2026 10:08 AM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
IOVA (Iovance Biotherapeutics Inc. Common Stock) at $8.48. True Sentiment Bullish, delta 40-60 call 74% / put 26%, call $141,870 vs put $49,495. RSI 26.4.
- Symbol
- IOVA
- Price
- $8.48
- Article bias (separate from True Sentiment)
- neutral
- Conviction
- low
- Published
- 2026-10-30 10:08:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)Options flow (2026-10-30 10:08) shows Bullish:
Call Volume: $141,870 (74.1%) Put Volume: $49,495 (25.9%) Total: $191,365
854 call contracts vs 244 put; 12 call trades vs 10 put. Pure directional conviction leans bullish near-term despite price collapse. Divergence: technicals bearish/oversold, sentiment bullish — matches spread engine note: "Divergence detected between technical indicators and options sentiment."
Key Statistics: IOVA
Fundamental Snapshot
Valuation
| EPS (trailing 12 mo) | $-0.72 |
| Market cap | $3.84B |
| Shares outstanding | 453.0M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 1.85 |
| 52-week low | $1.76 |
| 52-week high | $15.37 |
| Historical volatility | 99.6% |
Ownership & trading
| Institutional ownership | 35.0% |
| Average daily volume | 11.7M sh |
Reported figures; no analyst estimates.
📈 Analysis
News Headlines & Context
Iovance Biotherapeutics (IOVA) is a clinical-stage biotech focused on tumor-infiltrating lymphocyte (TIL) therapies. Based on general knowledge, recent context likely includes:
- FDA review updates or label expansions for Amtagvi (lifileucel) in melanoma and potentially other solid tumors.
- Q3 2026 earnings approaching, with focus on commercial launch uptake and cash burn.
- Possible clinical trial readouts from TIL pipeline candidates in cervical or lung cancer.
- Biotech sector volatility tied to rate expectations and healthcare policy headlines.
Context: A sharp intraday drop on 2026-10-29 (close $9.66 vs prior $14.70) may reflect a catalyst or broad biotech de-risking. Options sentiment is bullish via delta 40-60 flow, suggesting some traders expect a rebound despite weak technicals.
Fundamental Analysis
Based strictly on embedded fundamentals:
- Trailing EPS: -$0.72 (negative; no profitability).
- Trailing P/E: null (not applicable due to negative earnings).
- Forward P/E: null; PEG: null (no valuation multiples available).
- Market Cap: $3.84B; Shares Out: 452.97M.
- 52-week range: $1.76 to $15.37 (current $9.66 near lower-mid).
- Institutional ownership: 35.01% (moderate).
- Beta: 1.85 (high systematic risk).
- Historical Volatility: 99.64% (extreme).
- Dividend Yield: 0.00%; no dividend.
- Revenue, margins, ROE, D/E, FCF: null (not provided).
- Analyst target mean: null; recommendations: null.
Fundamentals show a pre-revenue/negative-earnings biotech with high volatility and no valuation anchors. This diverges from technical weakness (RSI 26.45) but aligns with options bullishness as a speculative recovery bet.
Current Market Position
Current price (2026-10-29 close): $9.66. Minute bars show 2026-10-29 opened $10.70, high $11.58, low $9.35, closed $9.66 on 52.16M volume (vs 20d avg 11.23M). 2026-10-30 09:40 bar: open $8.81, high $8.81, low $8.46, close $8.48, vol 1.03M — continued downside.
Key levels from data: 30-day low $9.35, 30-day high $15.37. Daily close support near $9.35; resistance from prior consolidation $13.00–$14.70.
Technical Indicators
Technical Analysis
Price $9.66 is below SMA 5 ($13.32), SMA 20 ($13.90), SMA 50 ($11.38) — bearish alignment, no bullish crossover. RSI 26.45 indicates oversold momentum. MACD (0.46) above signal (0.37), histogram +0.09, mildly bullish divergence vs price drop. Bollinger lower band $11.65; price below band = expansion/oversold. 30-day range $9.35–$15.37; price at 0% of range (near low).
True Sentiment Analysis (Delta 40-60 Options)
Options flow (2026-10-30 10:08) shows Bullish:
Call Volume: $141,870 (74.1%) Put Volume: $49,495 (25.9%) Total: $191,365
854 call contracts vs 244 put; 12 call trades vs 10 put. Pure directional conviction leans bullish near-term despite price collapse. Divergence: technicals bearish/oversold, sentiment bullish — matches spread engine note: "Divergence detected between technical indicators and options sentiment."
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.